pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IMNMImmunome Inc.

$IMNM20.90+0.05%
Bothell, WA, USupdated 18h ago

The immunome is the set of genes that code for proteins which constitute the immune system, excluding those that are widespread in other cell types, and not involved in the immune response itself. It is further defined as the set of peptides derived from the proteome that interact with the immune system. There are numerous ongoing efforts to characterize and sequence the immunomes of humans, mice, and elements of non-human primates.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 2Phase 3: 1
2Phase 11Phase 3
Phase 3
varegacestat
Desmoid Tumors
Phase 1
IM-1021
Diffuse Large B-Cell Lymphoma
Phase 1
IM-3050
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 10, 2026
earnings
$IMNM20.90+0.05%
2mo ago
Immunome Inc. earnings
Immunome Inc.
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Immunome Inc. jobs →

News

  • Argenx jumps on Phase 3 data for blockbuster Vyvgart
    The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
    biopharma_dive · 1mo ago
identifiers
ticker
$IMNM
SEC CIK
0001472012
country
US
source
sec_tickers
top tags
Oncology2DLBCL1NSCLC1Pulmonary Fibrosis1Pulmonology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?